Zogenix (ZGNX) Given Media Sentiment Rating of 0.10
Media headlines about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zogenix earned a news impact score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.7351777895326 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX) (americanbankingnews.com)
- Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008 (reuters.com)
- Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome – GlobeNewswire (press release) (globenewswire.com)
A number of analysts have recently issued reports on ZGNX shares. Mizuho restated a “buy” rating and set a $51.00 price target on shares of Zogenix in a report on Wednesday, November 8th. JMP Securities started coverage on shares of Zogenix in a report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target for the company. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, January 27th. Finally, ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Zogenix presently has an average rating of “Buy” and a consensus target price of $42.67.
Zogenix (NASDAQ:ZGNX) last posted its earnings results on Tuesday, November 7th. The company reported ($1.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.16). Zogenix had a negative net margin of 309.76% and a negative return on equity of 99.61%. research analysts predict that Zogenix will post -4.45 earnings per share for the current year.
In related news, EVP Bradley S. Galer bought 1,346 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was purchased at an average price of $36.59 per share, for a total transaction of $49,250.14. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roger Hawley sold 63,203 shares of Zogenix stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $36.84, for a total transaction of $2,328,398.52. Following the completion of the sale, the director now owns 105,575 shares of the company’s stock, valued at approximately $3,889,383. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by company insiders.
WARNING: This article was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/10/zogenix-zgnx-given-media-sentiment-rating-of-0-10.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.